Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Advisory Committees

2010 Meeting Materials, Transmissible Spongiform Encephalopathies Advisory Committee


October 28-29, 2010

On October 28, 2010 the Committee will discuss: (1) FDA’s risk assessment for potential exposure to the variant Creutzfeldt - Jakob disease (vCJD) agent in U.S.-licensed plasma-derived Factor VIII and (2) labeling of blood and blood components and plasma-derived products, including plasma-derived albumin and products containing plasma-derived albumin, to address the possible risk of transmission of vCJD.

Page Last Updated: 06/09/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.